Dan Roberts, AMD Patient, Advocate & Founding Director of MD Support, Inc. and the International Macular Degeneration Support Group talks about his passion for educating others about AMD (Age-related macular degeneration). He also talks about how the Ellex 2RT®, a first of its kind laser treatment for macular degeneration, can improve the quality of life for patients with AMD and offer a solution to the burden of care placed on payers and society resulting from AMD.
In this health supplier segment, pediatric emergency physician and pain specialist, Dr. Amy Baxter discusses the barriers to effective non-opioid pain management. She has given up her practice to focus on devices she has invented to block out pain. She also talks about The Buzzy, which helps block needle pain for children. She is passionate about changing the pain treatment paradigm to include proven technologies like hers – and other non-pharma modalities – for the benefit of physicians, patient, and society as a whole.
Radiation oncologist, Dr. Jae Lee, and his patient, 38-year-old breast cancer survivor, Carolyn Graham, discuss proton therapy and the patient experience.
Artist and patient Lydia Emily Archibald who is a spokesperson and creative director for MS On My Mind, an interactive initiative launched by EMD Serono, discusses her role in the project. She is joined by Dr. Daniel Bandari, M.D., M.S. founder of the Multiple Sclerosis Center of California, who discusses the physical challenges and prevalence associated with MS.
Michelle Reese, Chief Programs Officer at the Healthy Start Coalition of Miami-Dade, discusses birth defects and prevention.
Anna Sundgren, Renal Disease Strategy Leader, Global Medicines Development at AstraZeneca, talks about what’s on the horizon for chronic kidney disease (CKD) patients, and the physicians that treat them — who’ve seen little innovation in treatment advancements in over 30 years.
David Arthur, CEO of Salarius Pharmaceuticals, discusses the enrollment in a Phase 1 trial for their lead program which is for the treatment of Ewing Sarcoma, a devastating pediatric illness whose current treatment is chemotherapy, radiation and/or tumor resection.
Dr. Dmitry Kravtsov, M.D., Vice President of Research & Development at Vanessa Research, Inc. (VRI), discusses the white paper “Addressing the Microvillus Inclusion Disease Knowledge Gap – A Comprehensive Case Analysis”. MVID is a rare genetic disease that afflicts infants with very severe diarrhea. Shylicine™ is the first-ever drug developed to treat microvillus inclusion disease.
Dr. CJ Barnum, Ph.D., Director of Neuroscience for INmune Bio discusses the award of a $1 million dollar grant from the Alzheimer’s Association to begin a clinical trial for a new Alzheimer’s treatment.
Andrew J. Cutler, MD, chief medical officer, Meridien Research, and an investigator on Adhansia XR™ (methylphenidate HCI) clinical studies, discusses the new FDA approval of Adlon Therapeutics Adhansia XR™ extended-release capsules Cll for the treatment of Attention-Deficit/Hyperactivity Disorder in patients 6 and older.